

Letter to the Editor

Concerns Regarding the Potential Drug Side Effects and Follow-Up Duration in the Study “Comparison of the Efficacy of Atorvastatin and Rosuvastatin in Preventing Atrial Fibrillation after Coronary Artery Bypass Grafting”

Dear Editor,

I am writing to express my appreciation for the article recently published in the *Journal of Tehran University Heart Center* by Zahra Samadifar et al,¹ titled “Comparison of the Efficacy of Atorvastatin and Rosuvastatin in Preventing Atrial Fibrillation after Coronary Artery Bypass Grafting: A Double-Blind Randomized Comparative Trial.” The study provides valuable insights into the comparative efficacy of atorvastatin and rosuvastatin in preventing atrial fibrillation after coronary artery bypass grafting.

While the research offers meaningful contributions, I would like to raise a concern regarding the absence of reported potential drug side effects. Statins are known for their lipid-lowering, anti-inflammatory, and antioxidant properties and may have various effects on the body. It is crucial to document any observed side effects to provide a comprehensive understanding of the safety profile of the drugs.

Additionally, I wish to address the duration of the follow-up period in this randomized controlled trial. The authors conducted a 3-month follow-up to assess outcomes, including mortality. While I acknowledge the need for a reasonable follow-up duration, it is essential to consider whether a 3-month period is sufficient to capture potential long-term effects, particularly concerning mortality and other adverse events. Some drug-related side effects and outcomes may not manifest within this relatively short timeframe. Extending the follow-up period could provide a more comprehensive understanding of the impact of the drugs.

I recommend that the authors consider addressing potential drug side effects in future publications and

discuss the choice of the 3-month follow-up duration, including its strengths and limitations. This consideration will enhance the completeness and interpretation of the study findings.

I commend the authors' efforts in contributing valuable research to the scientific community and believe that addressing these concerns will further strengthen the impact and relevance of their work.

| 74

Yours truly,

Fatemeh Omid, MD
Assistant Professor of Cardiology,
Shahid Beheshti University of Medical Sciences,
Department of Cardiology,
Imam Hossein Hospital,
Shahid Madani Street,
Tehran,
Iran.
Tel: +98 21 73430.
Fax: +98 21 7755-7069.
E-mail: Dr.fateme.omidi@gmail.com.
ORCID: 0000-0001-7302-9136

Reference

1. Samadifar Z, Aslanabadi N, Kazemi Arbat B, Separham A, Javanshir E. Comparison of the Efficacy of Atorvastatin and Rosuvastatin in Preventing Atrial Fibrillation after Coronary Artery Bypass Grafting: A Double-blind Randomized Comparative Trial. *J Tehran Heart Cent.* 2023;18(2):115-121.